AllianceBernstein’s Aldeyra Therapeutics ALDX Stock Holding History

AllianceBernstein’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$353K	Sell	68,140 -7,410	-10%	-$32.5K	﹤0.01%	2808
2025 Q4	$391K	Hold	75,550	–	–	﹤0.01%	2780
2025 Q3	$394K	Hold	75,550	–	–	﹤0.01%	2811
2025 Q2	$289K	Buy	75,550 +16,900	+29%	+$43.7K	﹤0.01%	2930
2025 Q1	$337K	Hold	58,650	–	–	﹤0.01%	2721
2024 Q4	$293K	Sell	58,650 -4,340	-7%	-$22.3K	﹤0.01%	2888
2024 Q3	$340K	Hold	62,990	–	–	﹤0.01%	2854
2024 Q2	$208K	Buy	62,990 +12,550	+25%	+$49.1K	﹤0.01%	3021
2024 Q1	$165K	Hold	50,440	–	–	﹤0.01%	2960
2023 Q4	$177K	Hold	50,440	–	–	﹤0.01%	3003
2023 Q3	$337K	Sell	50,440 -170,090	-77%	-$1.26M	﹤0.01%	2759
2023 Q2	$1.85M	Buy	+220,530	New	+$2.17M	﹤0.01%	1945
2022 Q1	–	Sell	-15,200	Closed	-$61K	–	3265
2021 Q4	$61K	Hold	15,200	–	–	﹤0.01%	3232
2021 Q3	$133K	Hold	15,200	–	–	﹤0.01%	3156
2021 Q2	$172K	Buy	+15,200	New	+$183K	﹤0.01%	3184
2020 Q2	–	Sell	-13,500	Closed	-$33K	–	3199
2020 Q1	$33K	Hold	13,500	–	–	﹤0.01%	3087
2019 Q4	$78K	Hold	13,500	–	–	﹤0.01%	3064
2019 Q3	$71K	Hold	13,500	–	–	﹤0.01%	3109
2019 Q2	$81K	Buy	+13,500	New	+$102K	﹤0.01%	3104

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AllianceBernstein's ALDX Position: Q1 2026 in Review

AllianceBernstein reduced its Aldeyra Therapeutics (ALDX) stake by 9.8% in Q1 2026, selling an estimated $32.5K and leaving 68,140 shares worth $353K. The position accounts for ﹤0.01% of the portfolio, ranked #2808.

AllianceBernstein first reported a position in ALDX in Q2 2019 and has held it in 19 quarters since. The position peaked at $1.85M in Q2 2023. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

AllianceBernstein held 68,140 shares of Aldeyra Therapeutics worth $353K as of Q1 2026.
AllianceBernstein sold 7,410 Aldeyra Therapeutics shares in Q1 2026, an estimated $32.5K.
Aldeyra Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2808 holding.
AllianceBernstein first reported a position in Aldeyra Therapeutics in Q2 2019 and has held it in 19 quarters since.
AllianceBernstein's Aldeyra Therapeutics position peaked at $1.85M in Q2 2023.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.